Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OMER vs EVMN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Captures Overall Composite Edge (54.1 HOLD vs 30.0 SELL), While EVMN Leads 3–2 on Growth & Valuation Pillars

OMER Overall Winner 6-Pillar Tally: OMER 2 – 3 EVMN (1 Tie) Matrix Metrics: OMER 8 – 2 EVMN

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $16.68 (73.0x Forward P/E, -189.5% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OMER vs EVMN
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$16.68
-4.63% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 73.0x
Beta / 30D Vol 1.82β · 54% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 74.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $17.47 · SMA50: $18.23
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47

6-Pillar Scorecard Institutional Category Breakdown (OMER 2 – 3 EVMN)

Columns: Metric · OMER · EVMN
1. Valuation Multiples OMER
Forward P/E 73.0x N/M
Trailing P/E 14.3x N/M
PEG Ratio 0.81x N/M
EV / Revenue 50.1x N/M
2. Growth & Scale OMER
Revenue Growth (YoY) +14.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $27M N/A
Market Cap $1.3B $315.5M
3. Profitability & Quality EVMN
Gross Margin 38.3% N/A
Operating Margin -189.5% 0.0%
Net Profit Margin 324.9% 0.0%
Return on Equity (ROE) -576.3% -69.5%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$49M -$75M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Debt $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 85.5% (28th %ile) 209.0% (53rd %ile)
Put/Call OI Skew 0.09x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OMER (8) vs EVMN (2)
Institutional Metric OMER EVMN Criterion Row Edge
Market Capitalization
Scale
$1.3B $315.5M Larger Scale OMER
Trailing P/E Ratio
Valuation
14.3x N/M Lower Multiple OMER
Forward P/E Ratio
Valuation
73.0x N/M Lower Multiple OMER
Revenue Growth (YoY)
Growth
+14.9% +0.0% Higher Growth OMER
Operating Margin (TTM)
Profitability
-189.5% 0.0% Higher Margin EVMN
Net Profit Margin
Profitability
324.9% 0.0% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-576.3% -69.5% Higher ROE EVMN
52-Week Range Position
Momentum
70% ($6–$21) 8% ($5–$33) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
1.82β · 54% Vol 1.05β · 118% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
54.1 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
$27M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 50.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$49M ($97M Net Debt) -$75M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +34.37 pp
OMER: +2.96% · EVMN: +37.33%
3M Horizon OMER +47.1 pp
OMER: -2.97% · EVMN: -50.07%
6M Horizon OMER +110.13 pp
OMER: +42.56% · EVMN: -67.57%
1Y Horizon OMER +226.64 pp
OMER: +165.61% · EVMN: -61.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OMER Revenue EVMN Revenue OMER Op. Margin EVMN Op. Margin Margin Leader
FY2015 $10M N/A -527.3% N/A OMER
FY2016 $40M N/A -130.4% N/A OMER
FY2017 $60M N/A -67.7% N/A OMER
FY2018 $30M N/A -375.7% N/A OMER
FY2019 $110M N/A -130.6% N/A OMER
FY2020 $70M N/A -212.6% N/A OMER
FY2024 N/A $10M N/A -1000.2% EVMN
FY2025 N/A $10M N/A -623.6% EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OMER CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 28th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OMER vs EVMN Key Questions & Quantitative Answers

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. OMER trades at $16.68 (73.0x Forward P/E, -189.5% operating margin) versus EVMN at $7.10 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

OMER leads the Growth & Scale pillar: OMER posts +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), OMER cumulative revenue shifted +600.0% while EVMN shifted +0.0%. In operating R&D and SG&A reinvestment, OMER deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.

OMER screens cheaper on headline valuation multiples. OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OMER (-576.3% ROE) versus EVMN (-69.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.82β · 54% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.